Navigation Links
Pufferfish neurotoxin may serve as treatment for cancer therapy related pain
Date:6/26/2013

HACKENSACK, N.J. (June 26, 2013)- Researchers at the Brain and Spine Institute at John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, are studying a possible alternative to side effect-ridden opioid-based medications to treat cancer-related pain. The active ingredient for the treatment is Tetrodotoxin, a neurotoxin found in pufferfish.

"Chemotherapy-induced neuropathic pain is a serious debilitating condition that occurs in over 40 percent of patients receiving chemotherapy," said Principal Investigator Samuel Goldlust, M.D., Co-Chief of the Brain and Spine Institute at John Theurer Cancer Center. "Tetrodotoxin has been found to be 3,000 times more potent than morphine without the negative side effects of opioids."

Caused by damage to neurons in the peripheral nervous system, chemotherapy-induced neuropathic pain is one of the most common reasons that cancer patients stop their treatment early, negatively affecting patient outcomes. For some patients, the symptoms persist after chemotherapy for months, years, or even indefinitely.

Until recently, chemotherapy-induced neuropathic pain, was treated primarily with opioids, anti-depressants or drugs primarily used to treat seizures. Scientists have learned more recently of the importance of sodium channels in the conduction of pain signals from peripheral nerves to the brain. Derived from a neurotoxin found in pufferfish, Tetrodotoxin targets sodium channels in the patient's peripheral nervous system. By blocking the sodium channels, Tetrodotoxin limits the conduction of pain signals to the central nervous system, offering relief from pain related to damage caused by chemotherapy.

Many species of marine pufferfish contain a large amount of Tetrodotoxin in their skin and tissues as an evolutionary adaptation to reduce predation. The dose used in this clinical trial needed for pain relief is approximately 300 times less than the total found in one fish.

"WEX is committed to developing a new class of non-opioid analgesics," said Mr. Walter Korz, VP, & General Manager of WEX Pharmaceuticals. "We are honored to have an institution such as John Theurer Cancer Center at HackensackUMC participating with Dr. Goldlust serving as Principal Investigator for this groundbreaking multicenter phase II clinical trial using Terodotoxin."

"Novel approaches to treatment are accelerating cancer care at an unprecedented rate," said Andre Goy M.D., M.S., Chairman and Director, and Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation of Regional Cancer Care Associates. "We believe it is important that our researchers are actively involved in shaping the future of cancer care through clinical trials such as this one."

"Clinical trials allow us to continue offering the most advanced treatments options to our patients to improve outcomes and quality of life," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer, Professor, and Vice President of Cancer Services and President of Regional Cancer Care Associates, LLC.


'/>"/>

Contact: Jon Byington
jon.byington@porternovelli.com
212-601-8208
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. MS researchers determine that brain reserve independently protects against cognitive decline in MS
2. University of New England and Partners Celebrate Opening of Portland Community Health Center at Riverton June 20 for Underserved Populations
3. Effective Environmental Services Launch New Websites to Serve Customers
4. Allsup Observes National HIV Testing Day June 27
5. Merrill DataSite Releases New Comments: Cash Reserves and M&A Options
6. New Water Select® Showerhead Valve Conserves Water & Saves Money
7. On The Road to Better Health – Newark Residents to Be Served by New Mobile Health Center
8. PD-like sleep and motor problems observed in α-synuclein mutant mice
9. Fuseideas Expands to Serve Midwest Clients
10. Allsup Observes National Disability Professionals Week – June 10-14
11. Newport Board Group, a National Business Advisory Firm of CEOs That Serves the Middle Market, Issues Guidance for Companies Considering a Sale in 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on Provistaco.com ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
Breaking Medicine Technology: